Unraveling The Key Questions in EGFR-Driven NSCLC Treatment - Episode 5

MARIPOSA: Clinical Implications

,

Panelists discuss how the MARIPOSA trial demonstrated strong efficacy with amivantamab plus lazertinib that appears comparable to FLAURA2’s results with osimertinib plus chemotherapy, although cross-trial comparisons should be interpreted cautiously given differences in study populations and the need for mature overall survival data from both trials.

EP. 1: EGFR mNSCLC: Treatment Overview and Challenges
EP. 2: FLAURA and FLAURA2: Key Efficacy and Safety Data
EP. 3: CNS Activity in EGFR mNSCLC
EP. 4: Managing AEs With Osimertinib
Now Viewing
EP. 5: MARIPOSA: Clinical Implications
EP. 6: EGFR mNSCLC: Future Directions

Video content above is prompted by the following:

  • MARIPOSA evaluated amivantamab with lazertinib. How does the progression-free survival and overall response rate data from MARIPOSA compare with the outcomes seen in FLAURA2?

Related Content:

Unraveling The Key Questions in EGFR-Driven NSCLC Treatment ClinicalVideo Series
Key Messages From the Breast Cancer ADC Data Set and Closing Remarks
Treatment Duration, Maintenance Concepts, and Development of New ADC Targets in Breast
Combination Approaches With ADCs and Emerging Clinical Strategies in Breast Cancer